159 related articles for article (PubMed ID: 20217513)
1. Clinical approaches to preserve beta-cell function in diabetes.
Wajchenberg BL
Adv Exp Med Biol; 2010; 654():515-35. PubMed ID: 20217513
[TBL] [Abstract][Full Text] [Related]
2. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies in type 2 diabetes mellitus.
Chia CW; Egan JM
J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
[TBL] [Abstract][Full Text] [Related]
5. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
6. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
7. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
8. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
9. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 and type 2 diabetes: physiology and new clinical advances.
Combettes MM
Curr Opin Pharmacol; 2006 Dec; 6(6):598-605. PubMed ID: 16987706
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
12. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
Gallwitz B
Treat Endocrinol; 2005; 4(6):361-70. PubMed ID: 16318402
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 based therapy for type 2 diabetes.
Arulmozhi DK; Portha B
Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based Therapies for Type 2 Diabetes.
McIntosh CH
Can J Diabetes; 2008; 32(2):131-9. PubMed ID: 27056542
[TBL] [Abstract][Full Text] [Related]
16. Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn PH
Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
[TBL] [Abstract][Full Text] [Related]
17. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibitors and diabetes therapy.
McIntosh CH
Front Biosci; 2008 Jan; 13():1753-73. PubMed ID: 17981665
[TBL] [Abstract][Full Text] [Related]
19. Cellular glucose availability and glucagon-like peptide-1.
Park JH; Earm YE; Song DK
Prog Biophys Mol Biol; 2011 Nov; 107(2):286-92. PubMed ID: 21907232
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1, glucose homeostasis and diabetes.
Holst JJ; Deacon CF; Vilsbøll T; Krarup T; Madsbad S
Trends Mol Med; 2008 Apr; 14(4):161-8. PubMed ID: 18353723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
